GenusLSE:GNS -0.95%74 Gross Margin % is 0.00% as of Dec. 2025. GuruFocus rates LSE:GNS with a GF Score™ of 74/100 and a GF Value™ of £20.62 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, Genus ranks worse than 75.96% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Genus's Gross Profit for the
six
months ended in Dec. 2025 was £335.6 Mil. Genus's Revenue for the
six
months ended in Dec. 2025 was £335.6 Mil. Therefore, Genus's Gross Margin % for the quarter that ended in Dec. 2025 was 0.00%.
If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Genus's Gross Margin % or its related term are showing as below:
LSE:GNS'
s Gross Margin % Range Over the Past 10 Years
Min: 21.69 Med: 26.71 Max: 30.38
Current: 30.38
During the past 13 years, the highestGross Margin % of Genus was 30.38%. The lowest was 21.69%. And the median was 26.71%.
LSE:GNS's Gross Margin % is ranked worse than 75.96% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs LSE:GNS: 30.38
Genus had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Genus was 1.20% per year.
Genus (LSE:GNS) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genus had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genus Gross Margin % Related Terms
Genus Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genus's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:GNS vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Genus's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genus's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genus (LSE:GNS) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Genus and its competitors. Over the past decade, Genus' Gross Margin % has ranged from 21.69 to 30.38. According to the industry distribution chart, Genus ranks #556 out of 732 companies in the Biotechnology industry, placing it in the top 76%.
Is Genus' Gross Margin % too high?
Genus' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 21.69 to a high of 30.38. Based on the distribution chart, Genus ranks #556 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genus has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genus' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #556 out of 732 companies for Gross Margin %. This places Genus in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, Genus' own Gross Margin % has ranged from 21.69 to 30.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genus and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genus's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Based on GuruFocus' analysis, Genus (LSE:GNS) is currently considered Modestly Overvalued. The stock's GF Value™ is £20.62, compared to a current price of £22.90 — trading 11.1% above its estimated fair value. The current Gross Margin % is 0.00%. Genus' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genus (LSE:GNS), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (LSE:GNS) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of £22.90 is trading 11.1% above its estimated GF Value™ of £20.62.
GuruFocus considers Genus to be Modestly Overvalued.
Key valuation signals for LSE:GNS:
Gross Margin %: 0.00%
GF Value™: £20.62 vs. price of £22.90 (11.1% above fair value)
No single metric tells the full story. See the LSE:GNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
74GF Score
Get the complete analysis for LSE:GNS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:GNS has been successfully added to your 
